Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010

Abstract Objective Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. Methods Irish epidemiological data on patient numbers and m...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2009, Vol.12 (1), p.10-15
Main Authors: Bennett, Kathleen, PhD, Kabir, Zubair, MD, PhD, Barry, Michael, MD, Tilson, Lesley, PhD, Fidan, Dogan, PhD, Shelley, Emer, MD, Capewell, Simon, MD
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
CHD mortality
Coronary Disease - economics
Coronary Disease - mortality
Coronary Disease - prevention & control
Cost effectiveness
Cost-Benefit Analysis - trends
Female
heart disease
Heart diseases
Humans
IMPACT model
Internal Medicine
Interventions
Ireland
Ireland - epidemiology
Life Expectancy - trends
Male
Middle Aged
Models, Biological
Mortality
Secondary prevention
Secondary Prevention - economics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. Methods Irish epidemiological data on patient numbers and median survival in specific groups, plus the uptake, effectiveness, and costs of specific interventions, all stratified by age and sex, were incorporated into a previously validated CHD mortality model, the IMPACT model. This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention. Results In 2000, medical and surgical treatments together prevented or postponed approximately 1885 CHD deaths in patients aged 25 to 84 years, and thus generated approximately 14,505 extra life-years (minimum 7270, maximum 22,475). In general, all the cardiac interventions investigated were highly cost-effective in the Irish setting. Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions (
ISSN:1098-3015
1524-4733
DOI:10.1111/j.1524-4733.2008.00398.x